Literature DB >> 12930602

The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.

Nikola Besic1, Barbara Vidergar-Kralj, Snjezana Frkovic-Grazio, Tadeja Movrin-Stanovnik, Marija Auersperg.   

Abstract

It is generally believed that Hürthle cell thyroid carcinoma (HCTC) does not accumulate radioactive iodine (RAI). The aim of our retrospective study was to find out if, after thyroid surgery and RAI ablation of the thyroid remnant, the metastatic or recurrent HCTC accumulates RAI. We reviewed the charts of 48 patients with histopathologically verified HCTC, who were treated at the Institute of Oncology in Ljubljana, Slovenia, from 1972 to 2000. In 16 patients (11 women, five men; 47-77 years old), who had distant metastases at presentation (eight patients) or recurrence (eight patients), whole-body RAI scanning was performed after the withdrawal of thyroid hormone replacement. Whenever RAI uptake was confirmed, the therapy with 5.6 GBq of RAI was performed. In 11 of 16 patients, the uptake (range 0.1-12%) of RAI was confirmed. Altogether, 46 therapeutic applications of RAI were given. We conclude that whole-body scanning with RAI should be performed in HCTC. RAI may be effective in the treatment of HCTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930602     DOI: 10.1089/105072503322238845

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  22 in total

1.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

2.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Authors:  Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

3.  Development and validation of a prognostic nomogram for Hürthle cell thyroid carcinoma: a SEER-based study.

Authors:  Cong Shen; Yunzhe Zhao; Xiangyuan Qiu; Peng Li; Ying Ding; Wenlong Wang; Botao Sun; Xinying Li; Wei Jiang
Journal:  Gland Surg       Date:  2022-03

4.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

5.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

6.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

7.  Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Authors:  Ian Ganly; Vladimir Makarov; Shyamprasad Deraje; YiYu Dong; Ed Reznik; Venkatraman Seshan; Gouri Nanjangud; Stephanie Eng; Promita Bose; Fengshen Kuo; Luc G T Morris; Inigo Landa; Pedro Blecua Carrillo Albornoz; Nadeem Riaz; Yuri E Nikiforov; Kepal Patel; Christopher Umbricht; Martha Zeiger; Electron Kebebew; Eric Sherman; Ronald Ghossein; James A Fagin; Timothy A Chan
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

8.  Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2021-08-22       Impact factor: 3.845

9.  Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report.

Authors:  Nikola Besic; Barbara Vidergar-Kralj; Katja Zaletel; Cvetka Grasic-Kuhar
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

Review 10.  Inherited Thyroid Tumors With Oncocytic Change.

Authors:  Marcelo Correia; Ana Rita Lima; Rui Batista; Valdemar Máximo; Manuel Sobrinho-Simões
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.